Savvy Trades and Investments

[indievestments]

PS. I have pivoted my thinking on Sensus acquiring Skincure. I actually think the market would like it quite a lot since it is a bit more scalable IMO vs 1 time capital sale + 180 day terms.

The way I see it, if Skincure has 100 machines in the field, seeing on average 10 patients per month and a 60/40% split with clinics on Vision reimbursements (I understand $5k for Vision given extra diagnostic features, so lets call it $2,500 per patient), that is $2.5M per month / $30M per year. Joe said patient volume is growing 25% per year at all the clinics and there is some pricing leverage built in with potential CPT 77401 code revaluation next year or 2021.

Plus the Vision’s only cost Sensus $125-$150k to produce assuming 67% margins and $375k-$400k ASP. Would make for fast payback. I wonder if Arthur would go for that given his high standards discussed on the podcast.

Anyway, cashflow from SRT procedures could definitely fund IORT and direct SRT sales to derm’s. I’d guess the market would assign nice multiple to SRT procedure revenue.

I spoke with receptionist at http://middlesexdermatology.com/. They got a Vision in Q1 (from Skincure) and she said patients are happy and patient flow sounds pretty good.